Veru announces appointment of dr. erik swenson and dr. robert schooley to its infectious disease scientific advisory board

Miami, fl, june 01, 2023 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for sars-cov-2 and other viral ards-related diseases, today announced the appointment of erik swenson, m.d., a world-renowned pulmonologist specializing in critical care, and robert schooley, m.d., an accomplished infectious disease physician and researcher, to its infectious disease scientific advisory board (sab) to join david d. ho, m.d., a trailblazer of infectious disease viral research and therapeutic development, who is chairman of the sab.
VERU Ratings Summary
VERU Quant Ranking